Pulmonary Drugs Market Briefing on Growing at a CAGR of 8.1% From 2017 to 2025 – Coherent Market Insights
SEATTLE, March 17, 2021, (PHARMIWEB) — Pulmonary drugs are widely used to treat diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. Some of the pulmonary drugs are administered with the help of devices called nebulizers or inhalers. These drugs offer medications for all types of pulmonary disease which is expected to raise the market growth in the future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated with the help of appropriate medication, which has boosted the efforts of manufacturers to develop efficient and effective pulmonary drugs and medications.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1285
The global pulmonary drug market was valued at US$ 28.1 billion in 2016 and is expected to witness a robust CAGR of 8.1% over the forecast period (2017 – 2025).
Figure 1. Global Pulmonary Drugs Market (US$ Mn), by Region, 2016
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Quick Buy – Pulmonary Drugs Market Research Report: https://bit.ly/3tvi1Z4
Rising users of tobacco smoking are expected to augment market growth
The growing incidence of Chronic Obstructive Pulmonary Disease (COPD) is mainly caused by tobacco smoking and its exposure. According to the World Health Organization (WHO) 2016, tobacco smoking is the primary cause of COPD leading to around 90% of COPD cases. The severe damage caused due to smoke may lead to the adoption of lifestyle adjustments and medical treatments which include consumption of bronchodilators, inhaled glucocorticoids, inhaled steroids, and other pulmonary drugs to relieve the disease symptoms, hence boosting demand for pulmonary drugs. The number of smokers is high around the globe and does not have any drop in the past few years, they are highly prone to respiratory diseases such as COPD and asthma. For instance, according to the Centers for Disease Control and Prevention (CDC), the average rate of smokers in 2012 was 1 in 5 people, which was reported to be constant in the Burden of Tobacco use in the U.S. released in 2015.
North America is dominating the overall pulmonary drugs market and this can be attributed to the rising consumption of Inhaled corticosteroids (ICS) and Long-acting beta-agonists (LABA) combinational products. According to Ontario Drug Policy Research Network, 2015, ICS+LABA combination products are the second-most commonly prescribed inhaled respiratory medications for all indications in Canada, with 1.1 million prescriptions dispensed in the fourth quarter of 2013, whereas, short-acting beta-agonists (e.g., salbutamol) are the most frequently prescribed inhaled respiratory medications in Canada with 1.8 million prescriptions dispensed in the same time period.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/pulmonary-drugs-market-to-surpass-us-562-billion-threshold-by-2025-globally-594
Rising initiatives of government and non-government to fuel the market growth
The government and non-government are increasing their support in the form of initiatives and funds for providing sufficient medical care and education regarding the preventive measures as well as for developing appropriate medications to limit the life-threatening diseases such as COPD. For instance, in 2016, according to the World Health Organization (WHO), more than 90% of deaths were reported due to COPD in low and middle-income economies. Thus, the WHO initiated a Global Alliance against Chronic Respiratory Diseases (GARD) with a vision to provide required medical treatments to patients suffering from chronic respiratory diseases in low and middle-income economies. This provision demands a significant quantity of medication that is expected to propel the pulmonary drug market. Also, in 2015, the Bill and Melinda Gates Foundation granted a US$ 89 Mn funding to Novavax, to develop RSV F (Respiratory Syncytial Virus) Vaccine for pregnant women in low sourced countries as maternal immunization vaccine to protect respiratory infections in the children. Asia Pacific market is projected to be the fastest-growing region owing to the continuous marketing of new brands by manufacturers to consolidate and strengthen the sales of the products. For instance, in 2016, Lupin Limited and Novartis Healthcare Private Limited (NHPL) entered into a co-marketing agreement to promote Novartis’s Indacaterol / Glycopyrronium inhaler in India for treating COPD under the brand name of Loftair.
The major players operating the global pulmonary drugs market are Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi farmaceutici S.p.A., Zambon Company S.p.A., Alexia SAS, and Merck Sharp & Dohme Limited.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- Regulatory Scenario
- Pipeline Analysis
- Promotional Activities and Campaigns
- Supply Chain Analysis
- PEST Analysis
- Epidemiology
- Market Dynamics
- Global Pulmonary Drugs Market, By Drug Class, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- Inhaled Corticosteroids
- Long-Acting Beta-2 Agonists
- Antihistamines
- Vasodilators
- Short-Acting Beta-2 Agonists
- Others
- Introduction
- Global Pulmonary Drugs Market, By Application, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- Asthma & COPD
- Allergic Rhinitis
- Pulmonary Arterial Hypertension
- Cystic Fibrosis
- Others
- Introduction
- Global Pulmonary Drugs Market, By Distribution Channel, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
- Introduction
- Global Pulmonary Drugs Market, By Region, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 – 2025
- North America
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- Brazil
- Mexico
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of APAC
- Middle East
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Application, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis (3×3 Matrix)
- Company Profiles
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
